Lonza is doubling down on US and ADC expansion with its Merck CDMO deal
Lonza’s deal to acquire almost all of Merck KGaA’s US contract development and manufacturing organisation (CDMO) network will significantly boost…
All articles by Dominic Tyer
Dominic Tyer
Dominic Tyer is a Senior Editor at GlobalData overseeing PharmSource’s editorial content. He has more than 25 years of pharmaceutical publishing experience as a journalist and editor at leading UK, European and global industry titles. Contact Dom.
-
-
Gaelic Labs: the EU Critical Medicines Act will have a positive impact on supply
One of the standout M&A deals in 2025 was concluded as that year drew to a close. December 2025 saw…
-
CPHI 2026: Finding the right CDMO partner in an age of consolidation
Consolidation among contract development and manufacturing organisations (CDMOs) has been a regular theme for the sector, given that scale is…
-
CPHI 2026: Moderna builds on its COVID-era manufacturing lessons
Moderna Therapeutics is well acquainted with managing evolution, so perhaps it’s no surprise that the firm’s vice president of drug…
-
Looking beyond short-term turmoil, Syngene is investing for the future
These are transitional times for Syngene, the Bengaluru, India-headquartered contract research, development, and manufacturing organisation (CRDMO). It already has an…
-
BMS Texas investment advances pharma’s modular manufacturing agenda
The pharmaceutical industry’s emerging use of modular manufacturing approaches at scale is set to move up a level with a…
-
Samsung Biologics: geographic diversification is a sound business decision
South Korean contract development and manufacturing organisation (CDMO) Samsung Biologics has been on a steep upward growth trajectory since receiving…
-
BIO 2026: Indiana, biopharma investment and the Lilly effect
The US drive to onshore biopharmaceutical manufacturing has yielded billions of dollars of industry investment, raising the stakes for states…
-
BIO 2026: Cell and gene therapy firms outline their use of AI in manufacturing
Complexity is inherent to cell and gene therapy and that includes its manufacturing, where moving towards producing products at a…
-
Dangerous waters: Geopolitics, supply chains and access to medicines
Shortages of medicines for conditions such as diabetes, attention deficit hyperactivity disorder (ADHD) and hormone replacement therapy (HRT) have long…